Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
ADMA Biologics files $250M mixed securities shelf  16:50
05/28/21
05/28
16:50
05/28/21
16:50
ADMA

ADMA Biologics

$1.75 /

+0.015 (+0.86%)

 
ShowHide Related Items >><<
ADMA ADMA Biologics
$1.75 /

+0.015 (+0.86%)

ADMA ADMA Biologics
$1.75 /

+0.015 (+0.86%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
ADMA ADMA Biologics
$1.75 /

+0.015 (+0.86%)

ADMA ADMA Biologics
$1.75 /

+0.015 (+0.86%)

ADMA ADMA Biologics
$1.75 /

+0.015 (+0.86%)

Over a month ago
Earnings
ADMA Biologics reports Q1 EPS (16c), consensus (17c) » 16:30
05/12/21
05/12
16:30
05/12/21
16:30
ADMA

ADMA Biologics

$1.69 /

-0.03 (-1.74%)

Reports Q1 revenue…

Reports Q1 revenue $16.05, consensus $14.58M. "ADMA has successfully transformed its business in the early months of 2021 and in doing so set the stage for what the Company expects to be a strong year of growth and achievements. We remain on track to deliver on several strategic and financial objectives over the near term, and visibility is improving on the Company's path to profitability," said Adam Grossman, president and CEO of ADMA Biologics. "We achieved multiple milestones across business segments during the quarter, while at the same time delivered on operating commitments to shareholders, specifically, generating record quarterly revenues of $16.0 million, a 57% increase over the same period last year. Also on the financial front, ADMA successfully narrowed both gross losses as well as net losses compared to the prior quarter, an encouraging trend the Company will strive to continue in the coming quarters and accelerate throughout 2022."

ShowHide Related Items >><<
ADMA ADMA Biologics
$1.69 /

-0.03 (-1.74%)

ADMA ADMA Biologics
$1.69 /

-0.03 (-1.74%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
ADMA ADMA Biologics
$1.69 /

-0.03 (-1.74%)

ADMA ADMA Biologics
$1.69 /

-0.03 (-1.74%)

ADMA ADMA Biologics
$1.69 /

-0.03 (-1.74%)

Options
Unusually active option classes on open April 28th » 09:40
04/28/21
04/28
09:40
04/28/21
09:40
ADMA

ADMA Biologics

$1.90 /

+ (+0.00%)

, VXRT

Vaxart

$8.34 /

+ (+0.00%)

, SHOP

Shopify

$1,157.17 /

+0.57 (+0.05%)

, NVAX

Novavax

$257.52 /

+ (+0.00%)

, DISCA

Discovery

$39.03 /

+ (+0.00%)

, KMI

Kinder Morgan

$16.99 /

+ (+0.00%)

, LVS

Las Vegas Sands

$60.73 /

+ (+0.00%)

, GSX

Symbol now GOTU

$31.99 /

+ (+0.00%)

, SLV

iShares Silver Trust

$24.38 /

+ (+0.00%)

, MRO

Marathon Oil

$11.04 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Adma Biologics (ADMA), Vaxart (VXRT), Shopify (SHOP), Novavax (NVAX), Discovery (DISCA), Kinder Morgan (KMI), Las Vegas Sands (LVS), GSX Techedu (GSX), iShares Silver Trust (SLV), and Marathon Oil (MRO).

ShowHide Related Items >><<
VXRT Vaxart
$8.34 /

+ (+0.00%)

SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

NVAX Novavax
$257.52 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

KMI Kinder Morgan
$16.99 /

+ (+0.00%)

GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

DISCA Discovery
$39.03 /

+ (+0.00%)

ADMA ADMA Biologics
$1.90 /

+ (+0.00%)

ADMA ADMA Biologics
$1.90 /

+ (+0.00%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
VXRT Vaxart
$8.34 /

+ (+0.00%)

03/04/21 B. Riley
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley
Vaxart price target lowered to $16 from $22 at B. Riley Securities
10/13/20 B. Riley
B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
09/09/20 B. Riley
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

04/23/21 Baird
Shopify price target lowered to $1550 from $1600 at Baird
04/21/21 Citi
Shopify price target raised to $1,475 from $1,315 at Citi
04/05/21 Evercore ISI
Shopify initiated with an In Line at Evercore ISI
04/05/21 Credit Suisse
Shopify assumed with a Neutral at Credit Suisse
NVAX Novavax
$257.52 /

+ (+0.00%)

04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
03/26/21 B. Riley
Novavax selloff on 'rumored' production delay overdone, says B. Riley
03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
DISCA Discovery
$39.03 /

+ (+0.00%)

04/07/21 Deutsche Bank
Discovery price target raised to $60 from $35 at Deutsche Bank
03/26/21
Fly Intel: Top five analyst downgrades
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
KMI Kinder Morgan
$16.99 /

+ (+0.00%)

04/27/21 Citi
Kinder Morgan price target raised to $17 from $15.50 at Citi
04/22/21 RBC Capital
Kinder Morgan price target raised to $17 from $16 at RBC Capital
04/22/21 Mizuho
Kinder Morgan price target raised to $20 from $19 at Mizuho
03/09/21
Fly Intel: Top five analyst downgrades
LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

04/22/21 Credit Suisse
Las Vegas Sands price target raised to $69 from $58 at Credit Suisse
04/20/21 JPMorgan
Las Vegas Sands should be bought ahead of sentiment turn, says JPMorgan
04/19/21 Jefferies
Las Vegas Sands price target raised to $71 from $66 at Jefferies
04/07/21 Truist
Truist sees NY budget agreement's mobile sports betting deal as 'clear as mud'
GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

04/27/21 Goldman Sachs
GSX Techedu upgraded to Buy from Sell at Goldman Sachs
04/07/21
Fly Intel: Top five analyst upgrades
04/07/21 JPMorgan
GSX Techedu upgraded to Neutral from Underweight at JPMorgan
03/29/21
Fly Intel: Top five analyst upgrades
SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

04/23/21 Wolfe Research
Marathon Oil upgraded to Outperform from Peer Perform at Wolfe Research
04/13/21 Barclays
Marathon Oil price target raised to $13 from $9 at Barclays
03/23/21 Goldman Sachs
Marathon Oil assumed with a Sell at Goldman Sachs
03/23/21 Citi
Marathon Oil price target raised to $12 from $9 at Citi
VXRT Vaxart
$8.34 /

+ (+0.00%)

SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

NVAX Novavax
$257.52 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

KMI Kinder Morgan
$16.99 /

+ (+0.00%)

GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

DISCA Discovery
$39.03 /

+ (+0.00%)

ADMA ADMA Biologics
$1.90 /

+ (+0.00%)

  • 14
    Apr
  • 23
    Feb
  • 16
    Sep
  • 08
    May
SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

NVAX Novavax
$257.52 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

KMI Kinder Morgan
$16.99 /

+ (+0.00%)

GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

DISCA Discovery
$39.03 /

+ (+0.00%)

VXRT Vaxart
$8.34 /

+ (+0.00%)

SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

NVAX Novavax
$257.52 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

KMI Kinder Morgan
$16.99 /

+ (+0.00%)

GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

DISCA Discovery
$39.03 /

+ (+0.00%)

ADMA ADMA Biologics
$1.90 /

+ (+0.00%)

VXRT Vaxart
$8.34 /

+ (+0.00%)

SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

SHOP Shopify
$1,157.17 /

+0.57 (+0.05%)

NVAX Novavax
$257.52 /

+ (+0.00%)

MRO Marathon Oil
$11.04 /

+ (+0.00%)

LVS Las Vegas Sands
$60.73 /

+ (+0.00%)

KMI Kinder Morgan
$16.99 /

+ (+0.00%)

GSX Symbol now GOTU
$31.99 /

+ (+0.00%)

DISCA Discovery
$39.03 /

+ (+0.00%)

ADMA ADMA Biologics
$1.90 /

+ (+0.00%)

SLV iShares Silver Trust
$24.38 /

+ (+0.00%)

On The Fly
Fly Intel: Pre-market Movers » 09:02
04/28/21
04/28
09:02
04/28/21
09:02
CALT

Calliditas Therapeutics

$29.04 /

+0.14 (+0.48%)

, ADMA

ADMA Biologics

$1.90 /

+0.04 (+2.16%)

, SHOP

Shopify

$1,157.17 /

-7.43 (-0.64%)

, BSX

Boston Scientific

$42.37 /

+0.11 (+0.26%)

, HUM

Humana

$449.06 /

+2.66 (+0.60%)

, GD

General Dynamics

$185.95 /

+0.74 (+0.40%)

, SWK

Stanley Black & Decker

$207.74 /

+1.45 (+0.70%)

, IPG

Interpublic Group

$29.86 /

+0.14 (+0.47%)

, EAT

Brinker

$65.58 /

+0.21 (+0.32%)

, GOOG

Alphabet

$2,307.58 /

-18.91 (-0.81%)

, GOOGL

Alphabet Class A

$2,290.20 /

-19.4 (-0.84%)

, BA

Boeing

$242.28 /

+0.89 (+0.37%)

, ADP

ADP

$195.89 /

+0.77 (+0.39%)

, SPOT

Spotify

$293.22 /

-4.905 (-1.65%)

, SIRI

Sirius XM

$6.28 /

-0.075 (-1.18%)

, DISCA

Discovery

$39.03 /

+0.21 (+0.54%)

, MSFT

Microsoft

$262.19 /

+0.61 (+0.23%)

, PLX

Protalix

$5.84 /

-0.28 (-4.58%)

Check out this morning's…

ShowHide Related Items >><<
SWK Stanley Black & Decker
$207.74 /

+1.45 (+0.70%)

SPOT Spotify
$293.22 /

-4.905 (-1.65%)

SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

PLX Protalix
$5.84 /

-0.28 (-4.58%)

MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

IPG Interpublic Group
$29.86 /

+0.14 (+0.47%)

HUM Humana
$449.06 /

+2.66 (+0.60%)

GOOGL Alphabet Class A
$2,290.20 /

-19.4 (-0.84%)

GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

GD General Dynamics
$185.95 /

+0.74 (+0.40%)

EAT Brinker
$65.58 /

+0.21 (+0.32%)

DISCA Discovery
$39.03 /

+0.21 (+0.54%)

CALT Calliditas Therapeutics
$29.04 /

+0.14 (+0.48%)

BSX Boston Scientific
$42.37 /

+0.11 (+0.26%)

BA Boeing
$242.28 /

+0.89 (+0.37%)

ADP ADP
$195.89 /

+0.77 (+0.39%)

ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

CALT Calliditas Therapeutics
$29.04 /

+0.14 (+0.48%)

02/26/21
Fly Intel: Top five analyst initiations
02/26/21 H.C. Wainwright
Calliditas Therapeutics initiated with a Buy at H.C. Wainwright
07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

04/23/21 Baird
Shopify price target lowered to $1550 from $1600 at Baird
04/21/21 Citi
Shopify price target raised to $1,475 from $1,315 at Citi
04/05/21 Evercore ISI
Shopify initiated with an In Line at Evercore ISI
04/05/21 Credit Suisse
Shopify assumed with a Neutral at Credit Suisse
BSX Boston Scientific
$42.37 /

+0.11 (+0.26%)

04/15/21 Atlantic Equities
Atlantic Equities starts Boston Scientific at Overweight
04/15/21 Atlantic Equities
Boston Scientific initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
03/03/21 Piper Sandler
Piper Sandler still positively inclined on Boston Scientific after Lumenis deal
HUM Humana
$449.06 /

+2.66 (+0.60%)

04/16/21 Stephens
Humana named a new Best Idea for 2021 at Stephens
04/08/21 Gordon Haskett
Gordon Haskett highlights Encompass Health's 'interesting' Rhode Island trip
01/13/21 Deutsche Bank
DaVita price target raised to $150 from $105 at Deutsche Bank
01/06/21 Argus
Humana price target raised to $450 from $430 at Argus
GD General Dynamics
$185.95 /

+0.74 (+0.40%)

04/08/21 Wolfe Research
General Dynamics downgraded to Underperform from Outperform at Wolfe Research
03/29/21 Cowen
General Dynamics price target raised to $210 from $183 at Cowen
03/25/21 Citi
General Dynamics price target raised to $200 from $160 at Citi
01/29/21 Susquehanna
General Dynamics price target raised to $180 from $162 at Susquehanna
SWK Stanley Black & Decker
$207.74 /

+1.45 (+0.70%)

04/13/21 Deutsche Bank
Stanley Black & Decker price target raised to $221 from $215 at Deutsche Bank
04/07/21 JPMorgan
Stanley Black & Decker price target raised to $206 from $200 at JPMorgan
04/06/21 Barclays
Stanley Black & Decker price target raised to $219 from $214 at Barclays
03/12/21
Fly Intel: Top five analyst upgrades
IPG Interpublic Group
$29.86 /

+0.14 (+0.47%)

04/22/21 BMO Capital
Interpublic Group downgraded to Market Perform from Outperform at BMO Capital
02/19/21 BMO Capital
Interpublic Group price target raised to $28 from $23 at BMO Capital
12/15/20 Citi
Interpublic Group price target raised to $29 from $24 at Citi
12/11/20 Barclays
Interpublic Group initiated with an Overweight at Barclays
EAT Brinker
$65.58 /

+0.21 (+0.32%)

04/15/21 Wells Fargo
Brinker price target raised to $76 from $62 at Wells Fargo
04/12/21 JPMorgan
Brinker price target raised to $78 from $72 at JPMorgan
04/09/21 Deutsche Bank
Brinker price target raised to $72 from $63 at Deutsche Bank
04/01/21 MKM Partners
Brinker price target raised to $82 from $75 at MKM Partners
GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

04/28/21 Oppenheimer
Alphabet price target raised to $2,510 from $2,350 at Oppenheimer
04/28/21 Credit Suisse
Alphabet price target raised to $2,755 from $2,500 at Credit Suisse
04/28/21 Morgan Stanley
Morgan Stanley says Alphabet Search results a positive read for Facebook, Amazon
04/28/21 Monness Crespi
Alphabet price target raised to $3,000 from $2,500 at Monness Crespi
GOOGL Alphabet Class A
$2,290.20 /

-19.4 (-0.84%)

04/28/21 BMO Capital
Alphabet price target raised to $2,700 from $2,600 at BMO Capital
04/28/21 Truist
Alphabet price target raised to $2,500 from $2,200 at Truist
BA Boeing
$242.28 /

+0.89 (+0.37%)

04/15/21 Credit Suisse
Boeing price target raised to $233 from $193 at Credit Suisse
04/14/21 JPMorgan
Boeing price target raised to $260 from $230 at JPMorgan
04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
ADP ADP
$195.89 /

+0.77 (+0.39%)

03/24/21 Jefferies
ADP price target raised to $200 from $197 at Jefferies
02/10/21 Mizuho
ADP initiated with a Buy at Mizuho
02/01/21 Barclays
ADP price target raised to $197 from $180 at Barclays
01/29/21
Fly Intel: Top five analyst upgrades Spire
SPOT Spotify
$293.22 /

-4.905 (-1.65%)

04/22/21 Jefferies
Jefferies starts Spotify at Buy, sees 'more platform than streaming service'
04/22/21 Jefferies
Spotify initiated with a Buy at Jefferies
04/21/21 Atlantic Equities
Apple making push to fight Spotify for podcast creators, says Atlantic Equities
04/05/21 Evercore ISI
Spotify assumed with an Outperform at Evercore ISI
SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

02/03/21 Citi
Tax sharing agreement 'very bullish' for Liberty SiriusXM, says Citi
01/28/21
Fly Intel: Top five analyst downgrades
01/28/21 Credit Suisse
Sirius XM downgraded to Neutral after rally at Credit Suisse
01/27/21 Credit Suisse
Sirius XM downgraded to Neutral from Outperform at Credit Suisse
DISCA Discovery
$39.03 /

+0.21 (+0.54%)

04/07/21 Deutsche Bank
Discovery price target raised to $60 from $35 at Deutsche Bank
03/26/21
Fly Intel: Top five analyst downgrades
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

04/28/21 Morgan Stanley
Microsoft price target raised to $300 from $290 at Morgan Stanley
04/28/21 Credit Suisse
Microsoft price target raised to $300 from $265 at Credit Suisse
04/28/21 BMO Capital
Microsoft price target raised to $290 from $280 at BMO Capital
04/28/21 Cowen
Microsoft price target raised to $295 from $280 at Cowen
PLX Protalix
$5.84 /

-0.28 (-4.58%)

12/31/20 H.C. Wainwright
Protalix data underscore value proposition for PRX-102, says H.C. Wainwright
SWK Stanley Black & Decker
$207.74 /

+1.45 (+0.70%)

SPOT Spotify
$293.22 /

-4.905 (-1.65%)

SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

IPG Interpublic Group
$29.86 /

+0.14 (+0.47%)

HUM Humana
$449.06 /

+2.66 (+0.60%)

GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

GD General Dynamics
$185.95 /

+0.74 (+0.40%)

EAT Brinker
$65.58 /

+0.21 (+0.32%)

DISCA Discovery
$39.03 /

+0.21 (+0.54%)

BSX Boston Scientific
$42.37 /

+0.11 (+0.26%)

BA Boeing
$242.28 /

+0.89 (+0.37%)

ADP ADP
$195.89 /

+0.77 (+0.39%)

ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

  • 14
    Apr
  • 23
    Feb
  • 12
    Feb
  • 29
    Jan
  • 16
    Sep
  • 05
    Jun
  • 22
    May
  • 08
    May
  • 07
    May
SPOT Spotify
$293.22 /

-4.905 (-1.65%)

SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

IPG Interpublic Group
$29.86 /

+0.14 (+0.47%)

HUM Humana
$449.06 /

+2.66 (+0.60%)

GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

GD General Dynamics
$185.95 /

+0.74 (+0.40%)

DISCA Discovery
$39.03 /

+0.21 (+0.54%)

BA Boeing
$242.28 /

+0.89 (+0.37%)

SPOT Spotify
$293.22 /

-4.905 (-1.65%)

SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

PLX Protalix
$5.84 /

-0.28 (-4.58%)

MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

HUM Humana
$449.06 /

+2.66 (+0.60%)

GOOGL Alphabet Class A
$2,290.20 /

-19.4 (-0.84%)

GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

GD General Dynamics
$185.95 /

+0.74 (+0.40%)

EAT Brinker
$65.58 /

+0.21 (+0.32%)

DISCA Discovery
$39.03 /

+0.21 (+0.54%)

BSX Boston Scientific
$42.37 /

+0.11 (+0.26%)

BA Boeing
$242.28 /

+0.89 (+0.37%)

SWK Stanley Black & Decker
$207.74 /

+1.45 (+0.70%)

SPOT Spotify
$293.22 /

-4.905 (-1.65%)

SIRI Sirius XM
$6.28 /

-0.075 (-1.18%)

SHOP Shopify
$1,157.17 /

-7.43 (-0.64%)

MSFT Microsoft
$262.19 /

+0.61 (+0.23%)

GOOGL Alphabet Class A
$2,290.20 /

-19.4 (-0.84%)

GOOG Alphabet
$2,307.58 /

-18.91 (-0.81%)

EAT Brinker
$65.58 /

+0.21 (+0.32%)

DISCA Discovery
$39.03 /

+0.21 (+0.54%)

BSX Boston Scientific
$42.37 /

+0.11 (+0.26%)

BA Boeing
$242.28 /

+0.89 (+0.37%)

ADP ADP
$195.89 /

+0.77 (+0.39%)

ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

Hot Stocks
ADMA Biologics receives FDA approval for increased IVIG production scale » 07:10
04/28/21
04/28
07:10
04/28/21
07:10
ADMA

ADMA Biologics

$1.90 /

+0.04 (+2.16%)

ADMA Biologics announced…

ADMA Biologics announced that the Food and Drug Administration has granted approval for the company's expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin. The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plant's total processing capacity from 400,000 liters to an anticipated peak throughput of up to 600,000 liters. ADMA now has FDA approval to produce BIVIGAM at an expanded capacity with the same quality as the previous manufacturing scale, while using the same equipment, release testing assays, disposables and labor force. The company anticipates this will translate into meaningful gross margin improvement as production throughput flows through the standard 7 to 12-month manufacturing cycle for plasma-derived therapies. With this approval, ADMA additionally will now be able to offer BIVIGAM in two vial sizes, both the 50 mL and 100 mL configurations.

ShowHide Related Items >><<
ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

ADMA ADMA Biologics
$1.90 /

+0.04 (+2.16%)

Hot Stocks
ADMA Biologics opens ADMA BioCenters Plasma Collection Facility in S.C. » 08:12
04/26/21
04/26
08:12
04/26/21
08:12
ADMA

ADMA Biologics

$1.89 /

-0.015 (-0.79%)

ADMA Biologics announced…

ADMA Biologics announced commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina. Pursuant to updated United States Food and Drug Administration guidance to obtain approval for plasma collection centers, sponsors are now required to collect plasma donations for 3 months prior to submitting a Biologics License Application filing. Accordingly, ADMA expects to file its BLA for the Goose Creek, S.C. plasma collection facility in approximately 3 months from center opening and anticipates a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site, and once FDA approved, it can utilize the plasma collected for further use in the manufacturing of life saving therapies. This new, state-of-the-art plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the plasma center expects to maintain a staff of up to 50 highly trained healthcare workers.

ShowHide Related Items >><<
ADMA ADMA Biologics
$1.89 /

-0.015 (-0.79%)

ADMA ADMA Biologics
$1.89 /

-0.015 (-0.79%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
ADMA ADMA Biologics
$1.89 /

-0.015 (-0.79%)

ADMA ADMA Biologics
$1.89 /

-0.015 (-0.79%)

Hot Stocks
ADMA Biologics raises view on plasma collection facilities to 10+ by 2024 » 16:47
03/25/21
03/25
16:47
03/25/21
16:47
ADMA

ADMA Biologics

$2.07 /

+0.095 (+4.82%)

"With the approval…

"With the approval of another plasma collection facility in early February, ADMA now has seven plasma collection facilities under its corporate umbrella at various stages of development and approval, including one facility pending Biologics License Application approval in the second half of this year, and two additional plasma collection centers which we intend to open and file BLAs during 2021. Accordingly, we have revised our previous guidance from building 5-10 plasma collection facilities by 2024 to our current expectation of having 10 or more plasma collection facilities in operation by 2024," noted the company.

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

Earnings
ADMA Biologics reports Q4 EPS (20c), consensus (16c) » 16:43
03/25/21
03/25
16:43
03/25/21
16:43
ADMA

ADMA Biologics

$2.07 /

+0.095 (+4.82%)

Reports Q4 revenue $14M,…

Reports Q4 revenue $14M, consensus $12.91M. "In a year full of unprecedented health and economic challenges due to the pandemic, the ADMA team's unwavering commitment produced remarkable achievements across all our business segments," said Adam Grossman, President and Chief Executive Officer of ADMA Biologics. "Operationally, while enacting all the medically recommended COVID-19 safeguards to protect our patients, employees and customers, we successfully expanded our plasma collection center network ahead of schedule and delivered on all of our manufacturing and regulatory objectives as a part of our supply chain enhancement initiatives. We generated record revenues of $42.2M despite COVID-19 headwinds, and because of our strong commercial execution, we confidently provided first-time peak annual revenue guidance of $250M or greater expected to be achieved in 2024 and additionally committed to reaching profitability no later than the first quarter of 2024. "On the financial front, we substantially strengthened our balance sheet with year-end 2020 assets totaling $207.7M, significantly growing inventories to a year-end balance of $81.5M as well as increasing accounts receivable and investments in property, plant and equipment. We look forward

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

ADMA ADMA Biologics
$2.07 /

+0.095 (+4.82%)

Over a quarter ago
Hot Stocks
ADMA Biologics receives FDA approval for Hepatitis B plasma collections » 08:17
03/03/21
03/03
08:17
03/03/21
08:17
ADMA

ADMA Biologics

$2.36 /

-0.045 (-1.87%)

ADMA Biologics announced…

ADMA Biologics announced that its plasma collection center located in Kennesaw, Georgia received approval from the Korean Ministry of Food and Drug Safety for the sale of source plasma into South Korea. In conjunction with the South Korean approval, ADMA additionally announced the Kennesaw plasma collection center received FDA approval to implement a Hepatitis B immunization program, enabling ADMA to collect source plasma from donors immunized with an FDA-licensed Hepatitis B vaccine.

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

Conference/Events
Raymond James to hold a virtual conference » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
JLL

Jones Lang LaSalle

$178.34 /

-0.7 (-0.39%)

, PODD

Insulet

$266.20 /

-4.54 (-1.68%)

, SMG

Scotts Miracle-Gro

$216.58 /

-8.37 (-3.72%)

, IDXX

Idexx Laboratories

$529.63 /

-7.96 (-1.48%)

, APLS

Apellis

$45.60 /

-2.13 (-4.46%)

, AVT

Avnet

$38.79 /

-0.62 (-1.57%)

, SBAC

SBA Communications

$246.29 /

-1.45 (-0.59%)

, LPTX

Leap Therapeutics

$2.36 /

-0.06 (-2.48%)

, RJF

Raymond James

$118.27 /

-2.71 (-2.24%)

, WY

Weyerhaeuser

$33.80 /

-1.26 (-3.59%)

, LZB

La-Z-Boy

$41.30 /

-0.7 (-1.67%)

, DXCM

DexCom

$391.96 /

-4.42 (-1.12%)

, ADMA

ADMA Biologics

$2.36 /

-0.045 (-1.87%)

, CTT

CatchMark Timber

$10.51 /

-0.08 (-0.76%)

, CACI

CACI

$219.02 /

-8.08 (-3.56%)

, BR

Broadridge

$143.68 /

-2.765 (-1.89%)

, CWST

Casella Waste

$61.15 /

+0.6 (+0.99%)

, FLXN

Flexion

$11.09 /

-0.32 (-2.80%)

, HOLX

Hologic

$74.81 /

+0.2 (+0.27%)

, VSAT

ViaSat

$52.77 /

-0.08 (-0.15%)

42nd Annual Institutional…

42nd Annual Institutional Investors Virtual Conference will be held on March 1-3.

ShowHide Related Items >><<
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

PODD Insulet
$266.20 /

-4.54 (-1.68%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

FLXN Flexion
$11.09 /

-0.32 (-2.80%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

CACI CACI
$219.02 /

-8.08 (-3.56%)

BR Broadridge
$143.68 /

-2.765 (-1.89%)

AVT Avnet
$38.79 /

-0.62 (-1.57%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

02/26/21 JPMorgan
Jones Lang LaSalle price target raised to $200 from $176 at JPMorgan
01/25/21 Goldman Sachs
Jones Lang LaSalle initiated with a Buy at Goldman Sachs
12/21/20 JPMorgan
Jones Lang LaSalle price target raised to $172 from $132 at JPMorgan
10/07/20 Keefe Bruyette
Jones Lang LaSalle downgraded to Market Perform at Keefe Bruyette
PODD Insulet
$266.20 /

-4.54 (-1.68%)

02/25/21 Oppenheimer
Insulet price target raised to $277 from $235 at Oppenheimer
02/24/21 Raymond James
Insulet price target raised to $296 from $282 at Raymond James
02/04/21 Piper Sandler
Tandem trades at 'significant discount' to Insulet, says Piper Sandler
01/29/21 Piper Sandler
Insulet downgraded to Neutral from Overweight at Piper Sandler
SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

02/04/21 Truist
Scotts Miracle-Gro price target raised to $270 from $250 at Truist
01/11/21 Raymond James
Scotts Miracle-Gro price target raised to $274 from $224 at Raymond James
01/07/21 Truist
Scotts Miracle-Gro price target raised to $250 from $180 at Truist
12/11/20
Fly Intel: Top five analyst upgrades
IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

02/17/21 Barclays
Idexx Laboratories initiated with an Overweight at Barclays
01/29/21 JPMorgan
Idexx Laboratories initiated with an Overweight at JPMorgan
08/17/20 Credit Suisse
Idexx Laboratories price target raised to $422 from $415 at Credit Suisse
08/04/20 Credit Suisse
Idexx Laboratories price target raised to $415 from $300 at Credit Suisse
APLS Apellis
$45.60 /

-2.13 (-4.46%)

01/29/21 Baird
Apellis assumed at Outperform at Baird
12/14/20 Roth Capital
Apellis price target raised to $73 from $50 at Roth Capital
12/10/20 Cowen
Apellis price target raised to $55 from $45 at Cowen
12/04/20 JPMorgan
Apellis price target raised to $87 from $50 at JPMorgan
AVT Avnet
$38.79 /

-0.62 (-1.57%)

02/23/21 Citi
Citi opens long Arrow Electronics, short Avnet pair trade
01/29/21 Loop Capital
Avnet price target raised to $39 from $32 at Loop Capital
01/19/21 Citi
Citi boosts Avnet target to $40, opens 'Positive Catalyst Watch'
12/14/20 Goldman Sachs
Avnet price target raised to $25 from $23 at Goldman Sachs
SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

02/23/21 Credit Suisse
SBA Communications price target lowered to $277 from $291 at Credit Suisse
02/23/21 Barclays
SBA Communications price target raised to $310 from $305 at Barclays
02/23/21 Deutsche Bank
SBA Communications price target lowered to $325 from $335 at Deutsche Bank
02/08/21 JPMorgan
JPMorgan downgrades SBA to Neutral on 'lukewarm' tower stance
LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

01/29/21 Baird
Leap Therapeutics assumed at Outperform at Baird
06/29/20 Piper Sandler
Leap Therapeutics initiated with an Overweight at Piper Sandler
RJF Raymond James
$118.27 /

-2.71 (-2.24%)

01/29/21 Citi
Citi opens 'Positive Catalyst Watch' on Raymond James, ups price target
01/15/21 Wells Fargo
Raymond James double upgraded to Overweight at Wells Fargo
01/15/21 Wells Fargo
Raymond James upgraded to Overweight from Underweight at Wells Fargo
01/05/21 Wolfe Research
Raymond James upgraded to Outperform from Peer Perform at Wolfe Research
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

02/01/21 DA Davidson
Weyerhaeuser price target raised to $34 from $29 at DA Davidson
12/04/20 Raymond James
Weyerhaeuser upgraded to Outperform from Market Perform at Raymond James
08/03/20
Fly Intel: Top five analyst downgrades
08/03/20 DA Davidson
Weyerhaeuser downgraded to Neutral from Buy at DA Davidson
LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

11/19/20 Raymond James
La-Z-Boy price target raised to $46 from $37 at Raymond James
10/19/20 Sidoti
La-Z-Boy upgraded to Buy from Neutral at Sidoti
06/25/20 Stifel
La-Z-Boy price target raised to $37 from $25 at Stifel
04/13/20 Sidoti
La-Z-Boy downgraded to Neutral from Buy at Sidoti
DXCM DexCom
$391.96 /

-4.42 (-1.12%)

02/12/21 Oppenheimer
DexCom price target raised to $449 from $415 at Oppenheimer
02/12/21 Citi
DexCom price target lowered to $480 from $485 at Citi
02/12/21 Piper Sandler
DexCom earnings selloff should be bought, says Piper Sandler
01/29/21 Piper Sandler
DexCom price target raised to $500 from $465 at Piper Sandler
ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
CTT CatchMark Timber
$10.51 /

-0.08 (-0.76%)

02/16/21 B. Riley
CatchMark Timber price target raised to $12.50 from $11 at B. Riley
02/12/21 RBC Capital
CatchMark Timber cut to Sector Perform at RBC Capital on more limited growth
02/12/21 RBC Capital
CatchMark Timber downgraded to Sector Perform from Outperform at RBC Capital
10/30/20 RBC Capital
CatchMark Timber upgraded to Outperform from Sector Perform at RBC Capital
CACI CACI
$219.02 /

-8.08 (-3.56%)

02/23/21 William Blair
William Blair reiterates Outperform on Leidos following quarterly results
01/29/21 Truist
CACI price target raised to $290 from $275 at Truist
01/27/21 Stifel
CACI 'very likely' to bid on Perspecta as well, says Stifel
09/22/20 JPMorgan
JPMorgan upgrades 'relatively resilient' CACI to Overweight
BR Broadridge
$143.68 /

-2.765 (-1.89%)

02/03/21 BTIG
Broadridge upgraded to Buy from Neutral at BTIG
12/18/20 Truist
Broadridge initiated with a Buy at Truist
12/18/20 Truist
Broadridge initiated with a Buy at Truist
08/17/20 JPMorgan
Broadridge price target raised to $152 from $142 at JPMorgan
CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

12/21/20
Fly Intel: Top five analyst initiations
12/21/20 BofA
Casella Waste initiated with a Neutral at BofA
10/15/20 Berenberg
Casella Waste initiated with a Buy at Berenberg
09/24/20 Stifel
Casella Waste upgraded to Buy at Stifel, in a position to sustain 7%-8% growth
FLXN Flexion
$11.09 /

-0.32 (-2.80%)

08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Credit Suisse
Flexion initiated with an Outperform at Credit Suisse
HOLX Hologic
$74.81 /

+0.2 (+0.27%)

02/22/21 BTIG
Hologic price target raised to $91 from $84 at BTIG
01/28/21 Wells Fargo
Hologic price target raised to $95 from $90 at Wells Fargo
12/08/20 Argus
Hologic price target raised to $100 from $85 at Argus
11/20/20
Fly Intel: Top five analyst downgrades
VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

02/12/21 Barclays
ViaSat price target raised to $65 from $53 at Barclays
02/05/21 William Blair
William Blair upgrades ViaSat, sees upside to $90-$110 per share
02/05/21 William Blair
ViaSat upgraded to Outperform from Market Perform at William Blair
01/07/21 William Blair
ViaSat win at Delta likely brings large upfront cost, says William Blair
WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

PODD Insulet
$266.20 /

-4.54 (-1.68%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

LPTX Leap Therapeutics
$2.36 /

-0.06 (-2.48%)

JLL Jones Lang LaSalle
$178.34 /

-0.7 (-0.39%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

FLXN Flexion
$11.09 /

-0.32 (-2.80%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

CTT CatchMark Timber
$10.51 /

-0.08 (-0.76%)

CACI CACI
$219.02 /

-8.08 (-3.56%)

BR Broadridge
$143.68 /

-2.765 (-1.89%)

AVT Avnet
$38.79 /

-0.62 (-1.57%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

  • 21
    Oct
  • 18
    Jun
  • 21
    May
  • 13
    May
SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

SBAC SBA Communications
$246.29 /

-1.45 (-0.59%)

RJF Raymond James
$118.27 /

-2.71 (-2.24%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

VSAT ViaSat
$52.77 /

-0.08 (-0.15%)

SMG Scotts Miracle-Gro
$216.58 /

-8.37 (-3.72%)

LZB La-Z-Boy
$41.30 /

-0.7 (-1.67%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

DXCM DexCom
$391.96 /

-4.42 (-1.12%)

CWST Casella Waste
$61.15 /

+0.6 (+0.99%)

APLS Apellis
$45.60 /

-2.13 (-4.46%)

WY Weyerhaeuser
$33.80 /

-1.26 (-3.59%)

IDXX Idexx Laboratories
$529.63 /

-7.96 (-1.48%)

HOLX Hologic
$74.81 /

+0.2 (+0.27%)

ADMA ADMA Biologics
$2.36 /

-0.045 (-1.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.